Strategic partnership in regenerative medicine

11 September 2015
Volume 31 · Issue 6

BioEden are teaming up with Precious Cells Group, a London based medtech company whose facilities specialise in enabling the harvesting and banking of stem cells from cord blood and peripheral blood derived stem cells amongst others platform technologies.

The energy and long term commitment by BioEden to support and make available the highest quality of tooth stem cell banking to the majority, will now extend their tooth stem cell banking services to the clients of Precious Cells.

BioEden have set the gold standard in stem cell harvesting and storage from teeth and today are operational in 22 countries.  Their specialist team comprises scientists, researchers and business leaders from around the globe.

Precious Cells will process the stem cells using  BioEden’s unique patented method within their purpose built state of the art cell and tissue processing facilities, whereas BioEden will manage the entire specialist tooth stem cell banking proposition. Both organisations operate under the highest quality and safety standards and are regulated and licensed by the Human Tissue Authority.

BioEden’s Group CEO, Tony Veverka, said, “Both companies are delighted to work together building on the excellent work in stem cell medicine thus far. We are proud to give parents the opportunity to bank their children’s tooth cells, and help them secure a better future.”

Athol Haas, vice president for mergers and acquisitions explains, "At Precious Cells Group, we are striving to build relationships and services with others in the regenerative medicine space. Our strategic partnership with the world's leading tooth stem cell bank is a breakthrough for positive co-operation within our industry.”